InsiderTrades

Form 4 for ASMB ASSEMBLY BIOSCIENCES, INC.

Accepted 2025-10-03 00:00:00 ET · period of report 2025-08-08 · accession 0001123292-25-000510 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-10-03 2025-08-08 ASMB GILEAD SCIENCES, INC. 10% P - Purchase — +2.30M 4.51M +104% —
DM 2025-10-03 2025-08-08 ASMB GILEAD SCIENCES, INC. 10% P - Purchase — +2.30M 1.15M New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-08-08 P A 2,295,920 — 4,505,391 D — — (F1) Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 2,295,920 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), Class A warrants to purchase 1,147,960 shares of Common Stock (the "Class A Warrants"), and Class B warrants to purchase 1,147,960 shares of Common Stock (the "Class B Warrants"), at a combined price of $19.60 per share of Common Stock and accompanying one half of one Class A Warrant and one half of one Class B Warrant.
2 Derivative Class B warrants to purchase Common Stock 2025-08-08 P A 1,147,960 — 1,147,960 D $21.60 · 2026-11-15 to 2026-12-31 1,147,960 Common Stock (F1) Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 2,295,920 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), Class A warrants to purchase 1,147,960 shares of Common Stock (the "Class A Warrants"), and Class B warrants to purchase 1,147,960 shares of Common Stock (the "Class B Warrants"), at a combined price of $19.60 per share of Common Stock and accompanying one half of one Class A Warrant and one half of one Class B Warrant. (F3) The Class B Warrants are exercisable at any time after November 15, 2026 and expire on December 31, 2026, provided that the Class B Warrants will automatically terminate in full and be extinguished and will no longer be exercisable in the event that the Issuer publicly announces prior to November 15, 2026 that the Issuer has received at least $75 million in the aggregate of non-dilutive capital in connection with a collaboration agreement. A holder of the Class B Warrants may not exercise the Class B Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
3 Derivative Class A warrants to purchase Common Stock 2025-08-08 P A 1,147,960 — 1,147,960 D $21.60 · — to — 1,147,960 Common Stock (F1) Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 2,295,920 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), Class A warrants to purchase 1,147,960 shares of Common Stock (the "Class A Warrants"), and Class B warrants to purchase 1,147,960 shares of Common Stock (the "Class B Warrants"), at a combined price of $19.60 per share of Common Stock and accompanying one half of one Class A Warrant and one half of one Class B Warrant. (F2) The Class A Warrants are exercisable at any time after the date of issuance and expire on the earlier of (i) five years from the date of issuance, or August 11, 2030, and (ii) the date that is 30 days after the public announcement that the Issuer has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. A holder of the Class A Warrants may not exercise the Class A Warrants if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.